Ron Renaud has a successful track record of selling biotech companies to Big Pharma, totaling $16 billion in the last 10 years. Despite his financial success, Renaud continues to stay active in the biotech industry. After overseeing the acquisition of Cerevel Therapeutics, he is now serving as the CEO of Kailera Therapeutics, a company focused on weight loss drug candidates. Renaud’s dedication to the biotech sector is evident, as he continues to lead and drive value for shareholders. This story was originally featured in Adam’s Biotech Scorecard, a newsletter exclusive to STAT+ subscribers.
Source link
STAT+: Ron Renaud, biotech’s serial CEO, is ready for a new assignment — and maybe another deal?
